Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENICAR vs A-POXIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Treatment of hypertension in adults and children ≥6 years,Off-label: Diabetic nephropathy, heart failure
Anxiety disorders,Alcohol withdrawal syndrome,Seizure disorders (adjunctive),Preoperative sedation
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (Cr Cl < 50 m L/min).
Prodrug olmesartan medoxomil is rapidly hydrolyzed to active olmesartan by esterases in gastrointestinal tract. Olmesartan is not metabolized by CYP450 enzymes and is excreted unchanged in bile and urine.
Extensively metabolized in the liver via CYP2C19 (major) and CYP3A4 (minor) to inactive metabolites. CYP2C19 polymorphisms significantly affect clearance.
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
Highly protein-bound (approximately 99%) to serum albumin.
95% bound to albumin.
Volume of distribution is approximately 17 L (0.2–0.3 L/kg), indicating limited extravascular distribution.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water with accumulation in tissues (brain, liver, kidneys).
Oral bioavailability is about 26–29% (absolute).
Oral: 80-90%; Intramuscular: 95-100%; no data for other routes.
No adjustment for GFR ≥30 m L/min. For GFR <30 m L/min, initial dose 20 mg once daily; maximum 40 mg/day.
No dosage adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), maximum dose 20 mg daily.
No adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe impairment (Child-Pugh C).
Mild impairment: no adjustment. Moderate-to-severe (Child-Pugh B/C): maximum dose 20 mg daily.
Safety and efficacy not established for pediatric patients <18 years.
Approved for GERD in children ≥1 year (weight-based: 0.5-1 mg/kg once daily; maximum 20 mg). Safety in infants <1 year not established.
Initial 20 mg once daily; caution due to potential for reduced renal function. Monitor BP and electrolytes.
No specific dose adjustment, but monitor renal function and for increased risk of Clostridium difficile infection and osteoporosis-related fractures.
No FDA black box warning.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve use for patients with inadequate alternatives.
May cause fetal harm if used during pregnancy,Avoid use in patients with severe renal impairment (Cr Cl <20 m L/min),Sprue-like enteropathy (severe chronic diarrhea with weight loss),Hypotension in volume-depleted patients,Hyperkalemia,Renal function deterioration in patients with renal artery stenosis
Risk of dependence and withdrawal reactions; avoid abrupt discontinuation. May cause CNS depression and impair cognitive function. Use caution in hepatic impairment and geriatric patients.
Concomitant use with aliskiren in patients with diabetes mellitus,History of hypersensitivity to any component of the product
Severe hepatic impairment, acute narrow-angle glaucoma, myasthenia gravis, hypersensitivity to benzodiazepines, concurrent use with potent CYP3A4 inhibitors.
No significant food interactions; may be taken with or without food. However, avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) if renal impairment is present or if taking potassium supplements.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Avoid alcohol. Taking with food may delay absorption but does not affect total bioavailability.
Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data are limited. Use in the second and third trimesters is known to cause fetal renal dysfunction, oligohydramnios, skull ossification deficits, and neonatal hypotension, hyperkalemia, and renal failure.
First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. Chronic use: Fetal hydantoin syndrome (craniofacial anomalies, growth deficiency, intellectual disability).
Minimal excretion into breast milk; M/P ratio is unknown. The American Academy of Pediatrics considers use compatible with breastfeeding, but caution is advised in preterm infants or those with renal impairment.
Excreted into breast milk; M/P ratio ~0.3-0.5. Infant serum levels may reach subtherapeutic concentrations. Risk of sedation and poor feeding. Consider risk-benefit; monitor infant for drowsiness and weight gain.
No dose adjustment typically required in pregnancy, but pharmacokinetic changes (increased volume of distribution, altered renal clearance) may necessitate careful blood pressure monitoring and dose titration. Avoid use during second and third trimesters if possible.
Enhanced clearance (up to 50% increase) in pregnancy requires dose adjustments to maintain therapeutic levels. Frequent monitoring of free phenytoin levels recommended; total levels may be misleading due to decreased albumin. Postpartum dose reduction likely needed.
BENICAR (olmesartan) is an angiotensin II receptor blocker (ARB) used primarily for hypertension. It demonstrates a dose-dependent antihypertensive effect with a once-daily dosing regimen. Monitor renal function and serum potassium, especially in patients with renal impairment or those on potassium-sparing diuretics. Avoid use in pregnancy (category D).
A-POXIDE is a potent benzodiazepine with rapid onset; use lowest effective dose to minimize tolerance. Monitor for respiratory depression, especially in elderly or those with COPD. Abrupt discontinuation may cause withdrawal seizures; taper gradually over weeks to months. Avoid concurrent use with other CNS depressants including alcohol.
Take exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to see full blood pressure lowering effect.,Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium (muscle weakness, slow heartbeat) or low blood pressure (dizziness, fainting).,Stay hydrated but avoid excessive dehydration (e.g., from diarrhea or vomiting).,Do not abruptly stop this medication without consulting your doctor.
Do not consume alcohol while taking this medication.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Do not stop taking abruptly; follow your doctor's instructions for tapering the dose.,Inform your doctor if you have a history of substance abuse or respiratory conditions.,Store at room temperature away from moisture and heat.,Take exactly as prescribed; do not increase dose without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BENICAR vs A-POXIDE, answered by our medical review team.
BENICAR is a Angiotensin II Receptor Blocker that works by Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.. A-POXIDE is a Benzodiazepine that works by GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENICAR and A-POXIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENICAR is: Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.. The standard adult dose of A-POXIDE is: GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENICAR and A-POXIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENICAR is classified as Category C. Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data a. A-POXIDE is classified as Category C. First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonata. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.